Supporting pharmaceutical industry in providing potential life-saving treatments to patients faster
MORRISVILLE, N.C.–(BUSINESS WIRE)–Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its partnership with Thermo Fisher Scientific to use the Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform, to deliver clinical trial lab results economically with unprecedented speed.
“Clinical trial oncology patients require lab testing before they can receive potential life-saving treatments, which makes lab testing turnaround time critical,” said Brian O’Dwyer, chief executive officer at Q2 Solutions. “Our efforts in developing assays and tests to identify and target different aspects of diseases are critical to drug discovery for pharma clients. Adding the capabilities of the Ion Torrent Genexus System has the potential to drastically reduce our time to deliver clinical reports to trial sites, thereby enabling patients’ access to investigational drugs faster.”
The Ion Torrent Genexus System improves turnaround time and minimizes human error for genome profiling, resulting in better delivery of services and further differentiating the Q2 Solutions service offering. With 70 percent of oncology drugs in development relying on genome profiling to uncover specific disease-causing mutations, this significant advancement in genomic technologies may help get the right therapy gets to the right patient quickly.
“Access to the latest technology to help meet the stringent demands from pharmaceutical clients has become essential in the age of genomic-driven medicine,” said Peter Silvester, senior vice president and president of Life Sciences Solutions at Thermo Fisher Scientific. “We are proud of this strategic relationship with Q2 Solutions and the opportunity it provides for Thermo Fisher to move healthcare forward.”
Genomic profiling is a laboratory method that is used to learn about the genes in a person or in a specific cell type and the way those genes interact with each other and with the environment. Genomic profiling is done in a privacy-protective manner and may be used to discover why some patients are diagnosed with certain diseases while others are not, or why patients react in different ways to the same drug. It may also be used to help develop new ways to diagnose, treat, and prevent diseases, such as cancer.
Q2 Solutions is committed to implementing transformational technology that has the potential to revolutionize how complex diseases are managed. In November 2019, Q2 Solutions announced a national U.S. expansion of its Genomics Center of Excellence in North Carolina to enhance its ability to provide innovative genomic testing in North America and to further enable harmonized genomic testing globally.
Q2 Solutions is further committed to protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes.
About Q2 Solutions
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. Q2 Solutions’ industry-leading genomic and bioinformatics services provide customers with DNA and RNA sequencing and other testing as well as the ability to mine data for invaluable insights for drug discovery, precision medicine and clinical development. Q2 Solutions works with clients, using a wide array of technology platforms, to ensure maximum efficiency and quality delivery for every study. A joint venture of IQVIA (formerly QuintilesIMS) and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. To learn more, visit www.q2labsolutions.com.
Click here to subscribe to Mobile Alerts for IQVIA.
Contacts
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144